Clinical trial
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater…
NCT00022906 · Corixa Corporation, Industry · Unknown status
Key facts
| NCT number | NCT00022906 |
|---|---|
| Title | Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement |
| Official title | Phase I, Dose-Escalation Study of Iodine-131 Anti-B1 Antibody For Patients With Previously Treated Non-Hodgkin's Lymphoma With More Than 25% Bone Marrow Involvement |
| Lead sponsor | Corixa Corporation, Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Unknown status |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Iodine-131 Anti-B1 Antibody |
| Enrollment | 24 |
| Start date | May 1, 1999 |
| First posted | Aug 17, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: